Skip to content

Clinical study on acupoint catgut embedding therapy for residual cough after post-acute swquelae of COVID-19

Clinical study on acupoint catgut embedding therapy for residual cough after post-acute swquelae of COVID-19

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067971
Enrollment
Unknown
Registered
2023-02-01
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

residual cough after post-acute swquelae of COVID-19

Interventions

control group:Oral methoxamine capsules

Sponsors

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Positive nucleic acid or antigen test of COVID-19 2. Cough from the onset of the disease, lingering, irritating dry cough, or accompanied by a small amount of white phlegm, the duration of 4-8 weeks 3. Visual analog scale (VAS) of cough severity >= 4 points 4. Lung CT examination showed no obvious abnormality or thickening of lung texture 5. Exclude cough caused by other causes 6. Age range from 18 to 65 years old 7. Informed consent, and voluntarily sign the informed consent

Exclusion criteria

Exclusion criteria: 1. Body temperature (axillary temperature) >= 37.0?; 2. Patients who had taken codeine, dextromethorphan, compound methoxamine capsules and other antitussive drugs within 24 hours before inclusion; 3. cough caused by chronic obstructive pulmonary disease, acute onset of chronic bronchitis, tuberculosis and other diseases; 4. complicated with serious primary diseases of cardiovascular and cerebrovascular systems, liver, kidney and hematopoietic systems and other organic diseases such as tumors; 5. Those who have language or hearing impairment, intellectual impairment, serious mental illness and other conditions that cannot cooperate; 6. Pregnant and lactating women and those who have fertility requirements in the past six months; 7. Allergic to the study drug; 8. Participants in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Reduction of VAS for cough severity;

Secondary

MeasureTime frame
Leicester Cough Questionnaire;Cough hypersensitivity questionnaire;Proportion of patients with VAS reduction =3 points;Cough remission and resolution time;

Countries

China

Contacts

Public ContactDai Qiufu

Department of Acupuncture and moxibustion, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

daiqiufu@126.com+86 10 87906910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026